Calidi Biotherapeutics, Inc. 8-K

What Happened
Calidi Biotherapeutics, Inc. filed an 8-K on May 29, 2026, disclosing an amended and restated warrant (the "Warrant") issued in a private placement to an accredited investor. The Warrant covers up to 17,391,304 unvested shares of common stock at an exercise price of $0.23. The amendment restates a May 6, 2026 warrant (previously disclosed in the company’s May 8, 2026 8-K) and makes several changes, including conditioning exercise and issuance of shares on approval by the company’s stockholders.

Key Details

• Warrant covers up to 17,391,304 shares of common stock; exercise price $0.23 per share.
• Exercise and issuance of shares now require approval of the company’s stockholders.
• Minimum Vesting Acquisition Amount increased from $500,000 to $1,000,000.
• Vesting Termination Date extended from July 8, 2026 to September 30, 2026.
• Issuance relied on Section 4(a)(2) and Rule 506(b) (private placement); investor represented as an accredited investor; shares issued on exercise are restricted from resale in the U.S. absent registration or an exemption.

Why It Matters
The amended warrant creates the possibility of up to 17.4 million new shares being issued if vesting conditions are met and shareholders approve exercise, which could affect Calidi’s share count and per-share metrics if exercised. The change raises the vesting threshold and extends the vesting window, which may delay or limit near-term issuance. Retail investors should watch for any upcoming stockholder vote and related disclosures that will determine whether and when these shares can be issued.